Immuneering Corporation Class A Common Stock is a biopharmaceutical company specializing in using computational biology to develop novel therapies for cancer and other diseases. Their innovative approach combines data science, artificial intelligence, and genomics to identify and target specific molecular pathways. With a strong pipeline of candidates, Immuneering is poised to make a significant impact in the field of precision medicine.
Notification